ReviewDiabetes, obesity & metabolism2021
Technology in the management of type 2 diabetes: Present status and future prospects.
Review in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06243536 (The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2025Pooled it
- A Systematic Review and Meta-Analysis of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Type-2 Diabetes.Medicina (Kaunas, Lithuania) · 2023Pooled it
- The Development of a Syringe-Based Insulin Applicator Using a Biodesign-Based Methodology.Biomimetics (Basel, Switzerland) · 2026Article
- Cost-effectiveness analysis comparing real-time continuous glucose monitoring with self-monitoring of blood glucose for patients with type 2 diabetes treated with insulin in Japan.Journal of diabetes investigation · 2026Article
- Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes.Microorganisms · 2026Review
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- The photoswitchable cannabinoid azo-HU308 enables optical control of CaFEBS open bio · 2026Article
- Mussel-Bioinspired Edible CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SMARTCLOTH Prototype for Dietary Management in Patients With Diabetes Mellitus: Tutorial on Human-Centered Design Methodology for Health Care Hardware Development.Journal of medical Internet research · 2026Article
- The application of AI-based interventions in diabetes personalized management: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2026Review
- Targeting the gut microbiome for type 2 diabetes management: a scoping review of systematic reviews and meta-analyses.Frontiers in endocrinology · 2026Article
- Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.BMC health services research · 2025Article
- Continuous Glucose Monitoring Systems Can Meet the Challenge of Glucose Management and Beyond in Individuals with Type 2 Diabetes: An Expert Multidisciplinary Position.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance.American journal of physiology. Endocrinology and metabolism · 2025Article
- Association of Health Information Literacy and Health Outcomes Among Individuals with Type 2 Diabetes and Metabolic Syndrome.Nursing reports (Pavia, Italy) · 2025Article
- Factors Influencing Psychological Insulin Resistance Among Patients with Type 2 Diabetes in China: A Structural Equation Model Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Home self-management of type 2 diabetes with diabetes technologies in northern France: a focused ethnographic study protocol.BMJ open · 2024Article
- Frailty Detection in Older Adults with Diabetes: A Scoping Review of Assessment Tools and Their Link to Key Clinical Outcomes.Journal of clinical medicine · 2024Article
- Carbohydrate Content Classification Using Postprandial Heart Rate Responses from Non-Invasive Wearables.Sensors (Basel, Switzerland) · 2024Article
- Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety.World journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The growing incidence of type 2 diabetes (T2D) is a significant health concern, representing 90% of diabetes cases worldwide. As the disease progresses, resultant insulin deficiency and hyperglycaemia necessitates insulin therapy in many cases. It has been recognized that a significant number of people who have a clinical requirement for insulin therapy, as well as their healthcare professionals, are reluctant to intensify treatment with insulin due to fear of hypoglycaemia, poor understanding of treatment regimens or lack of engagement, and are therefore at higher risk of developing complications from poor glycaemic control. Over the past decade, the rise of diabetes technologies, including dosing advisors, continuous glucose monitoring systems, insulin pumps and automated insulin delivery systems, has led to great improvements in the therapies available, particularly to those requiring insulin. Although the focus has largely been on delivering these therapies to the type 1 diabetes population, it is becoming increasingly recognized that people with T2D face similar challenges to achieve recommended glycaemic standards and also have the potential to benefit from these advances. In this review, we discuss diabetes technologies that are currently available for people with T2D and the evidence supporting their use, as well as future prospects. We conclude that there is a clinical need to extend the use of these technologies to the T2D population to curb the consequences of suboptimal disease management in this group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.